CAPRICOR THERAPEUTICS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CAPRICOR THERAPEUTICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $22.27M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $25.18M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $2.55M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $244.9K | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $310.3K | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $1.01M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $1.67M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $2.67M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $4.00M | Mar 22, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($105.04M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($40.47M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($22.29M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($29.02M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($20.02M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($13.66M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($7.64M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($15.19M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $2.43M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($18.81M) | Mar 22, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($108.14M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($42.56M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($24.08M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($29.70M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($20.94M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($13.69M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($7.73M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($15.33M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($12.86M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($16.98M) | Mar 22, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $84.45M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $49.97M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $36.45M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $21.82M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $13.57M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $8.46M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $5.14M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $12.07M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $10.77M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $16.04M | Mar 22, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($69.81M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($40.00M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($25.60M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $4.92M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($16.81M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($10.05M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($6.82M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($13.86M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($14.23M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($14.45M) | Mar 22, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.90M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.17M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $1.31M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $2.00M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $1.20M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $547.6K | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $316.5K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $32.2K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $192.0K | Mar 22, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $355.95M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $170.48M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $58.73M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $50.09M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $41.33M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $34.62M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $11.11M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $9.25M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $16.27M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $18.75M | Mar 22, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.16M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $25.02M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $36.13M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $38.31M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $9.96M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $6.42M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $4.27M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $4.63M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $5.05M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $22.75M | Mar 22, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $305.79M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $145.46M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $22.60M | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | $11.79M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $31.37M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $28.20M | Mar 17, 2023 |
| FY2021 | Dec 31, 2019 | $6.84M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $4.62M | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | $11.23M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | ($4.00M) | Mar 29, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2013 | $1.92M | Mar 16, 2015 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($304.88M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($199.83M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($159.37M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($137.08M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($108.06M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($88.04M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($74.38M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($66.74M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($51.55M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($53.98M) | Mar 22, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $287.85M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $11.29M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $14.69M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $9.60M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $34.89M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $32.67M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $3.90M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $4.26M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $6.14M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $3.20M | Mar 22, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 11, 2022 |
| FY2017 | Dec 31, 2017 | 0 | Mar 22, 2018 |
| FY2017 | Dec 31, 2016 | (1) | Mar 22, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 11, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Mar 29, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | (1) | Mar 22, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 57.37M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 45.58M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | 31.15M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | 25.24M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | 24.19M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | 20.58M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | 5.23M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | 3.14M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 26.27M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 21.40M | Mar 22, 2018 |